Abstract
Background It is unknown which commonly used Alzheimer disease (AD) biomarker values - baseline or progression - best predict longitudinal cognitive decline. Methods 526 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI composite memory and executive scores were the primary outcomes. Individual-specific slope of the longitudinal trajectory of each biomarker was first estimated. These estimates and observed baseline biomarker values were used as predictors of cognitive declines. Variability in cognitive declines explained by baseline biomarker values was compared with variability explained by biomarker progression values. Results About 40% of variability in memory and executive function declines was explained by ventricular volume progression among mild cognitive impairment patients. A total of 84% of memory and 65% of executive function declines were explained by fluorodeoxyglucose positron emission tomography (FDG-PET) score progression and ventricular volume progression, respectively, among AD patients. Conclusions For most biomarkers, biomarker progressions explained higher variability in cognitive decline than biomarker baseline values. This has important implications for clinical trials targeted to modify AD biomarkers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 690-703 |
| Number of pages | 14 |
| Journal | Alzheimer's and Dementia |
| Volume | 10 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 1 2014 |
Fingerprint
Keywords
- ADNI
- ADNI-exe
- ADNI-mem
- Biomarker
- Biomarker progressions
- Cognitive declines
- FDG-PET
- MCI
- MRI volume
ASJC Scopus subject areas
- Clinical Neurology
- Developmental Neuroscience
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health
- Geriatrics and Gerontology
- Epidemiology
- Health Policy
Cite this
Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. / Dodge, Hiroko; Zhu, Jian; Harvey, Danielle; Saito, Naomi; Silbert, Lisa; Kaye, Jeffrey; Koeppe, Robert A.; Albin, Roger L.
In: Alzheimer's and Dementia, Vol. 10, No. 6, 01.11.2014, p. 690-703.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease
AU - Dodge, Hiroko
AU - Zhu, Jian
AU - Harvey, Danielle
AU - Saito, Naomi
AU - Silbert, Lisa
AU - Kaye, Jeffrey
AU - Koeppe, Robert A.
AU - Albin, Roger L.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Background It is unknown which commonly used Alzheimer disease (AD) biomarker values - baseline or progression - best predict longitudinal cognitive decline. Methods 526 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI composite memory and executive scores were the primary outcomes. Individual-specific slope of the longitudinal trajectory of each biomarker was first estimated. These estimates and observed baseline biomarker values were used as predictors of cognitive declines. Variability in cognitive declines explained by baseline biomarker values was compared with variability explained by biomarker progression values. Results About 40% of variability in memory and executive function declines was explained by ventricular volume progression among mild cognitive impairment patients. A total of 84% of memory and 65% of executive function declines were explained by fluorodeoxyglucose positron emission tomography (FDG-PET) score progression and ventricular volume progression, respectively, among AD patients. Conclusions For most biomarkers, biomarker progressions explained higher variability in cognitive decline than biomarker baseline values. This has important implications for clinical trials targeted to modify AD biomarkers.
AB - Background It is unknown which commonly used Alzheimer disease (AD) biomarker values - baseline or progression - best predict longitudinal cognitive decline. Methods 526 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI composite memory and executive scores were the primary outcomes. Individual-specific slope of the longitudinal trajectory of each biomarker was first estimated. These estimates and observed baseline biomarker values were used as predictors of cognitive declines. Variability in cognitive declines explained by baseline biomarker values was compared with variability explained by biomarker progression values. Results About 40% of variability in memory and executive function declines was explained by ventricular volume progression among mild cognitive impairment patients. A total of 84% of memory and 65% of executive function declines were explained by fluorodeoxyglucose positron emission tomography (FDG-PET) score progression and ventricular volume progression, respectively, among AD patients. Conclusions For most biomarkers, biomarker progressions explained higher variability in cognitive decline than biomarker baseline values. This has important implications for clinical trials targeted to modify AD biomarkers.
KW - ADNI
KW - ADNI-exe
KW - ADNI-mem
KW - Biomarker
KW - Biomarker progressions
KW - Cognitive declines
KW - FDG-PET
KW - MCI
KW - MRI volume
UR - http://www.scopus.com/inward/record.url?scp=84927174962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927174962&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2014.04.513
DO - 10.1016/j.jalz.2014.04.513
M3 - Article
VL - 10
SP - 690
EP - 703
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 6
ER -